**Appendix A**

**US only, Industry Sponsored AD Trial Information (from ClinicalTrials.gov; accessed March 30, 2022)**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **NCT Number** | **Interventions** | **Phases** | **Trial Completion Date** | **Female** | **Male** | **White** | **Black or African American** | **Asian** | **Mixed** | **Other** | **Total Subjects** |
| NCT00105547 | Tarenflurbil (r-flurbiprofen; MPC-7869) | Phase 3 | May-08 | 840 | 809 | 1558 |  |  |  | 91 | **1,649** |
| NCT00574132 | bapineuzumab 0.5 mg/kg|Placebo Control|Bapineuzumab 1.0 m/kg | Phase 3 | Jun-12 | 588 | 526 | 1059 |  |  |  | 55 | **1,114** |
| NCT00575055 | bapineuzumab 0.5 mg/kg|Placebo Control|Bapineuzumab 1.0 m/kg | Phase 3 | Apr-12 | 600 | 490 | 1044 |  |  |  | 46 | **1,090** |
| NCT00000174 | Rivastigmine | Phase 3 |  | 532 | 486 |  |  |  |  |  | **1,018** |
| NCT00948766 | Rivastigmine 4.6 mg/24 h (5 cm^2)|Rivastigmine 9.5 mg/24 h (10 cm^2)|Rivastigmine 13.3 mg/24 h (15 cm^2)|Placebo | Phase 4 | Jun-12 | 461 | 255 | 625 | 47 |  |  | 44 | **716** |
| NCT00253201 | galantamine hydrobromide | Phase 3 | Oct-97 | 394 | 242 | 581 |  |  |  | 55 | **636** |
| NCT01741194 | AC-1204|Placebo | Phase 2|Phase 3 | 14-Apr-17 | 366 | 252 | 546 | 48 | 13 |  | 11 | **618** |
| NCT00235716 | dl-alpha-tocopherol|Memantine|Placebo | Phase 3 | Oct-12 | 19 | 594 | 529 | 80 | 1 | 1 | 2 | **613** |
| NCT00283725 | No intervention |  | Dec-06 | 342 | 231 | 508 | 42 | 6 |  | 17 | **573** |
| NCT00074529 | MK0677 | Phase 2 | Jan-06 | 326 | 237 | 495 |  |  |  | 68 | **563** |
| NCT02079909 | T-817MA-H|T-817MA-L|Placebo | Phase 2 | 5-May-17 | 252 | 217 | 428 | 26 | 8 | 2 | 5 | **469** |
| NCT00440050 | DHA (Docosahexaenoic Acid)|Placebo | Phase 3 | May-09 | 210 | 192 |  |  |  |  |  | **402** |
| NCT00566397 | PF-04494700|Placebo | Phase 2 | Dec-10 | 227 | 172 |  |  |  |  |  | **399** |
| NCT00568776 | bapineuzumab (ELND005) | Phase 2 | May-10 | 199 | 152 | 339 |  |  |  | 12 | **351** |
| NCT00555204 | ABT-089|placebo | Phase 2 |  | 184 | 150 | 318 | 10 |  |  | 6 | **334** |
| NCT02016560 | florbetapir F 18|Flortaucipir F18|Procedure: Brain PET Scan | Phase 2|Phase 3 | 28-Jul-17 | 151 | 158 | 291 | 12 | 3 | 0 | 3 | **309** |
| NCT00428389 | Drug: Rivastigmine 5 cm^2 transdermal patch|Drug: Rivastigmine 10 cm^2 transdermal patch | Phase 3 | Feb-08 | 151 | 110 |  |  |  |  |  | **261** |
| NCT00759863 | Behavioral: Lifezig | Phase 2 | Apr-09 | 196 | 46 |  |  |  |  |  | **242** |
| NCT00305903 | Rivastigmine, memantine | Phase 4 | Aug-07 | 135 | 99 | 206 |  |  |  | 28 | **234** |
| NCT00112073 | bapineuzumab|placebo | Phase 2 | Dec-08 | 125 | 104 | 220 |  |  |  | 9 | **229** |
| NCT01584440 | AVP-923-20|Placebo|AVP-923-30 | Phase 2 | 30-Jul-14 | 126 | 92 | 200 | 11 | 4 |  | 3 | **218** |
| NCT00083590 | Huperzine A | Phase 2 | Nov-07 | 135 | 75 |  |  |  |  |  | **210** |
| NCT02817906 | ITI-007|Placebo | Phase 3 | 30-Jan-19 | 101 | 74 | 148 | 20 | 4 | 1 | 2 | **175** |
| NCT00040443 | CX516|Placebo | Phase 2 | Jun-04 | 75 | 100 |  |  |  |  |  | **175** |
| NCT01677572 | Aducanumab (recombinant, fully human anti-AÎ² IgG1 mAb)|Placebo | Phase 1 | 31-Jul-19 | 83 | 82 |  |  |  |  |  | **165** |
| NCT03467477 | Flortaucipir F18|Procedure: Brain PET Scan | Phase 2 | 15-Nov-18 | 93 | 68 | 154 | 4 | 3 | 0 | 0 | **161** |
| NCT00960531 | Biological: ACC-001+ QS21 (3mcg)|Biological: ACC-001 (10 mcg) + QS-21|Biological: ACC-001+QS-21 (30mcg) | Phase 2 | Dec-13 | 94 | 66 | 156 | 3 | 0 | 0 | 1 | **160** |
| NCT00142805 | Tricaprilin|Placebo | Phase 2 | 7-Jan-07 | 85 | 67 | 151 | 1 |  |  |  | **152** |
| NCT01254773 | bapineuzumab | Phase 2 | Mar-13 | 84 | 62 | 142 | 4 |  |  |  | **146** |
| NCT00420420 | MK0249|Comparator: Placebo (unspecified) | Phase 2 | Aug-08 | 79 | 65 |  |  |  |  |  | **144** |
| NCT02431468 | Bryostatin 1|Placebo | Phase 2 | Feb-17 | 71 | 70 | 133 | 7 | 1 | 0 | 0 | **141** |
| NCT00843518 | LY451395|Placebo | Phase 2 | Jun-11 | 67 | 65 | 115 | 15 | 0 | 0 | 2 | **132** |
| NCT00359944 | AC-3933|Sugar Pill | Phase 2 | Sep-08 | 95 | 37 |  |  |  |  |  | **132** |
| NCT01284387 | Biological: ACC-001 (vanutide cridificar) | Phase 2 | Feb-14 | 71 | 55 | 122 | 1 | 3 |  |  | **126** |
| NCT03560245 | Bryostatin|Placebo | Phase 2 | 25-Jul-19 | 61 | 47 | 91 | 14 | 3 | 0 | 0 | **108** |
| NCT00702143 | florbetapir F 18 | Phase 2 | Dec-08 | 52 | 53 |  |  |  |  |  | **105** |
| NCT00230568 | Aricept | Phase 4 | Dec-07 | 73 | 32 |  |  |  |  |  | **105** |
| NCT00486044 | Simvastatin|Placebo | Phase 2 | Jun-09 | 70 | 30 |  |  |  |  |  | **100** |
| NCT02769234 | Procedure: ERP/EEG test|Procedure: Psychometric testing |  | Jul-17 | 51 | 48 |  |  |  |  |  | **99** |
| NCT00571064 | Donepezil HCl | Phase 4 | 22-Apr-09 | 65 | 32 |  |  |  |  |  | **97** |
| NCT00857506 | florbetapir F 18 | Phase 2 | Dec-11 | 42 | 41 |  |  |  |  |  | **83** |
| NCT00082602 | galantamine ER | Phase 3 | Apr-05 | 57 | 25 | 68 | 9 | 4 |  | 1 | **82** |
| NCT01548287 | AZD5213|Placebo | Phase 2 | Jan-13 | 56 | 25 |  |  |  |  |  | **81** |
| NCT01230853 | BAN2401; Active Comparator: A|Placebo Comparator B|Active Comparator B|Placebo Comparator A | Phase 1 | Feb-13 | 38 | 42 |  |  |  |  |  | **80** |
| NCT02795780 | Flortaucipir F18|Procedure: PET Scan | Phase 2 | 28-Aug-17 | 31 | 48 | 76 | 3 | 0 | 0 | 0 | **79** |
| NCT00663026 | bapineuzumab|placebo | Phase 2 | Oct-10 | 38 | 41 |  |  |  |  |  | **79** |
| NCT02353598 | Crenezumab dose level 1|Crenezumab dose level 2|Crenezumb dose level 3|Placebo | Phase 1 | 26-Mar-19 | 36 | 39 |  |  |  |  |  | **75** |
| NCT02322021 | E2609|Placebo | Phase 2 | 20-Dec-19 | 42 | 28 | 60 | 9 | 0 | 0 | 1 | **70** |
| NCT00141661 | PF-04494700 - Low Dose Arm|PF-04494700 - High Dose Arm|Placebo Comparator | Phase 2 | Jun-06 | 41 | 26 | 65 |  |  |  | 2 | **67** |
| NCT04079803 | Placebo oral tablet|Simufilam 100 mg tablet|Simufilam 50 mg oral tablet | Phase 2 | 31-Mar-20 | 35 | 29 | 55 | 8 | 1 | 0 | 0 | **64** |
| NCT00024531 | Atorvastatin calcium | Phase 2 | Aug-04 | 23 | 40 |  |  |  |  |  | **63** |
| NCT01227564 | Biological: ACC-001 3 Î¼g/ QS-21 50 Î¼g|Biological: ACC-001 10 Î¼g/ QS-21 50 Î¼g|Placebo- Phosphate buffered saline (PBS) | Phase 2 | Feb-14 | 33 | 30 |  |  |  |  |  | **63** |
| NCT00916617 | bapineuzumab | Phase 2 | Sep-12 | 30 | 31 |  |  |  |  |  | **61** |
| NCT00795418 | Biological: Placebo|Biological: CAD106 | Phase 2 |  | 23 | 35 | 56 | 1 |  |  | 1 | **58** |
| NCT01023685 | Biological: CAD106 | Phase 2 | Feb-12 | 23 | 35 | 56 | 1 |  |  | 1 | **58** |
| NCT02640092 | [18F]GTP1 | Phase 1 | 11-Jun-19 | 30 | 27 | 51 |  |  |  | 6 | **57** |
| NCT01397539 | BIIB037|Placebo | Phase 1 | Aug-13 | 36 | 17 | 48 | 3 | 1 |  | 1 | **53** |
| NCT03639987 | Aducanumab|Placebo | Phase 2 | 30-Jul-19 | 29 | 23 | 52 | 0 | 0 | 0 | 0 | **52** |
| NCT00329082 | LY2062430|Placebo | Phase 2 | May-08 | 28 | 24 | 50 |  |  |  | 2 | **52** |
| NCT00244322 | LY450139 dihydrate|placebo | Phase 2 | Dec-06 | 25 | 36 | 50 |  |  |  | 1 | **51** |
| NCT00766363 | EVP-6124 (0.1 mg/day)|EVP-6124 (0.3 mg/day)|EVP-6124 (1.0 mg/day)|Comparator: Placebo|Donepezil|Rivastigmine | Phase 1 | Mar-09 | 29 | 20 |  |  |  |  |  | **49** |
| NCT00916383 | Drug: 350 mg Donepezil Transdermal Patch|Drug: Placebo Patch | Phase 2 | Jun-09 | 29 | 20 |  |  |  |  |  | **49** |
| NCT00876863 | CERE-110: Adeno-Associated Virus injection Surgery|Procedure: Placebo Surgery | Phase 2 | 13-Aug-15 | 21 | 28 |  |  |  |  |  | **49** |
| NCT03520998 | GRF6019 | Phase 2 | 24-May-19 | 29 | 18 | 42 | 4 | 1 | 0 | 0 | **47** |
| NCT00476008 | Memantine|Placebo | Phase 4 | Oct-12 | 15 | 28 |  |  |  |  |  | **43** |
| NCT02185053 | CPC-201 | Phase 2 | 31-Jul-16 | 22 | 19 |  |  |  |  |  | **41** |
| NCT01565382 | florbetapir F 18 | Not Applicable | Feb-11 | 20 | 20 |  |  |  |  |  | **40** |
| NCT02560753 | T3D-959 | Phase 1|Phase 2 | 30-Jun-16 | 20 | 16 |  |  |  |  |  | **36** |
| NCT00982202 | pioglitazone|Placebo | Phase 2 | Jan-05 | 18 | 11 |  |  |  |  |  | **29** |
| NCT01374438 | MSDC-0160|Placebo | Phase 2 | May-13 | 16 | 13 | 25 | 4 | 0 | 0 | 0 | **29** |
| NCT02549196 | Donepezil|Solifenacin | Phase 2 | 28-Sep-17 | 14 | 14 | 25 | 3 |  |  |  | **28** |
| NCT03765762 | GRF6019|Placebo | Phase 2 | 17-Dec-19 | 16 | 10 | 25 | 0 | 1 | 0 | 0 | **26** |
| NCT00299988 | Intravenous Immunoglobulin|Placebo | Phase 2 | Apr-10 | 13 | 11 |  |  |  |  |  | **24** |
| NCT00539305 | testosterone gel|placebo gel | Phase 3 | May-12 | 0 | 22 |  |  |  |  |  | **22** |
| NCT01172145 | Modafinil|Placebo | Phase 3 | Sep-07 | 11 | 11 |  |  |  |  |  | **22** |
| NCT03117738 | AstroStem|Placebo-Control | Phase 1|Phase 2 | 31-Aug-19 | 9 | 12 | 19 |  | 2 |  |  | **21** |
| NCT01504958 | Device: Repetitive Transcranial Magnetic Stimulation (rTMS)|Behavioral: NICE Cognitive Training | Not Applicable | May-15 | 12 | 9 |  |  |  |  |  | **21** |
| NCT00120874 | Behavioral: Individualized management of AD including caregiver training|Memantine | Phase 4 | Nov-11 | 15 | 5 | 18 | 0 | 0 |  | 2 | **20** |
| NCT02256306 | Plasma | Not Applicable | Feb-17 | 12 | 6 | 18 |  |  |  |  | **18** |
| NCT01992380 | Flortaucipir F18|Procedure: Brain PET scan | Phase 1 | 30-May-14 | 16 | 14 | 18 | 0 | 0 | 0 | 0 | **18** |
| NCT01082965 | Donepezil|Placebo | Not Applicable | Jul-12 | 11 | 7 |  |  |  |  |  | **18** |
| NCT01565291 | florbetapir F 18 | Early Phase 1 | Jan-08 | 8 | 8 |  |  |  |  |  | **16** |
| NCT00988598 | PF-04447943|Placebo | Phase 1 | 5-Jul-10 | 10 | 5 |  |  |  |  |  | **15** |
| NCT02210286 | Dietary Supplement: Magtein | Not Applicable | Jul-16 | 7 | 8 |  |  |  |  |  | **15** |
| NCT00477659 | Donepezil hydrochloride | Phase 4 | 15-Aug-08 | 5 | 9 | 14 | 0 | 0 | 0 | 0 | **14** |
| NCT03748706 | PTI-125, 100 mg tablets | Phase 2 | 8-May-19 | 9 | 4 | 10 | 3 |  |  |  | **13** |
| NCT00255086 | Memantine|Placebo pill | Phase 3 | Feb-10 | 5 | 8 |  |  |  |  |  | **13** |
| NCT00855868 | florbetapir F 18|[11C]-PIB | Phase 2 | Jan-11 | 11 | 2 |  |  |  |  |  | **13** |
| NCT00551161 | memantine | Phase 4 | Dec-11 | 5 | 7 |  |  |  |  |  | **12** |
| NCT03298672 | NDX-1017|Placebo | Phase 1 | 5-Sep-19 | 6 | 5 | 11 | 0 | 0 |  |  | **11** |
| NCT00470418 | NIC5-15|Placebo | Phase 2 | Mar-10 | 4 | 6 |  |  |  |  |  | **10** |
| NCT03856359 | Rifaximin 550 milligrams (MG) | Phase 2 | 19-Nov-20 | 9 | 1 |  |  |  |  |  | **10** |
| NCT01028911 | PF-03654746|Placebo | Phase 1 | May-10 | 1 | 8 |  |  |  |  |  | **9** |
| NCT01565330 | florbetapir F 18 | Phase 1 | Aug-08 | 4 | 5 |  |  |  |  |  | **9** |
| NCT01059877 | Device: 1072nm infrared Photobiomodulation|Device: Photobiomodulation SIMULATED | Not Applicable | Feb-12 | 4 | 5 |  |  |  |  |  | **9** |
| NCT02423200 | VX-745 | Phase 2 | Nov-16 | 5 | 4 |  |  |  |  |  | **9** |
| NCT02221947 | Bryostatin 1|Placebo | Phase 1|Phase 2 | Dec-14 | 5 | 4 |  |  |  |  |  | **9** |
| NCT02370524 | [18F]T807 | Phase 1 | Jan-16 | 5 | 3 |  |  |  |  |  | **8** |
| NCT04474405 | Flortaucipir F18|Procedure: Brain PET Scan|Procedure: Whole body PET scan|Florbetapir F 18|Procedure: Brain MRI | Early Phase 1 | 9-Dec-13 | 3 | 4 | 7 |  |  |  |  | **7** |
| NCT01066546 | Dimebon tablet for oral administration | Phase 3 | Jul-10 | 3 | 2 |  |  |  |  |  | **5** |
| NCT02323334 | LY3202626|Placebo (Part A, B, C)|Itraconazole | Phase 1 | Feb-16 | 2 | 0 | 0 | 0 | 2 |  |  | **2** |